Page last updated: 2024-11-04

sb 239063 and Lung Injury, Acute

sb 239063 has been researched along with Lung Injury, Acute in 2 studies

SB 239063: structure in first source
SB-239063 : A member of the class of imidazoles carrying 4-hydroxycyclohexyl, 4-fluorophenyl and 2-methoxypyrimidin-4-yl substituents at positions 1, 4 and 5 respectively.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, G1
Zhang, Y1
Liu, X1
Fang, Q1
Wang, Z1
Fu, L1
Liu, Z1
Wang, Y1
Zhao, Y1
Li, X1
Liang, G1
Xiong, LL1
Tan, Y1
Ma, HY1
Dai, P1
Qin, YX1
Yang, RA1
Xu, YY1
Deng, Z1
Zhao, W1
Xia, QJ1
Wang, TH1
Zhang, YH1

Other Studies

2 other studies available for sb 239063 and Lung Injury, Acute

ArticleYear
Discovery of a New Inhibitor of Myeloid Differentiation 2 from Cinnamamide Derivatives with Anti-Inflammatory Activity in Sepsis and Acute Lung Injury.
    Journal of medicinal chemistry, 2016, Mar-24, Volume: 59, Issue:6

    Topics: Acute Lung Injury; Animals; Anti-Inflammatory Agents, Non-Steroidal; Binding Sites; Cinnamates; Cyto

2016
Administration of SB239063, a potent p38 MAPK inhibitor, alleviates acute lung injury induced by intestinal ischemia reperfusion in rats associated with AQP4 downregulation.
    International immunopharmacology, 2016, Volume: 38

    Topics: Acute Lung Injury; Animals; Aquaporin 4; Disease Models, Animal; Humans; Imidazoles; Intestines; Lun

2016